Ipamorelin

Description

Ipamorelin

Overview: Ipamorelin is a synthetic growth-hormone-releasing peptide (GHRP). It is a small pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist of the ghrelin/growth-hormone secretagogue receptor (GHS-R1a). By binding this receptor, it stimulates the pituitary to release endogenous growth hormone (GH). Originally developed by Novo Nordisk, Ipamorelin has since been studied in multiple clinical research settings.

Mechanism & What Makes It Different

Ipamorelin stimulates GH secretion through GHS-R activation but is distinct in its selectivity. Earlier GHRPs often elevated other pituitary hormones such as ACTH/cortisol, prolactin, LH/FSH, or TSH. Ipamorelin, by contrast, has been shown in most studies to increase GH release without significantly affecting those other pathways. This selective profile makes it a “cleaner” GH secretagogue for research purposes.

Pharmacology & Dosing (What Trials Show)

Pharmacokinetic and pharmacodynamic data in humans show:

• Onset & half-life: Short plasma half-life of ~1–2 hours after administration.
• Dosing effects: Dose-dependent GH peaks observed after subcutaneous or intravenous dosing.
• Pulse pattern: Because of its short duration, Ipamorelin produces discrete GH pulses rather than prolonged exposure.

Bottom Line

Ipamorelin is a potent and selective GH secretagogue. Its unique profile—stimulating GH release without markedly affecting other hormones—has made it an attractive candidate for research into growth hormone regulation.

Research Use Only: Ipamorelin is provided strictly for laboratory and research purposes. It is not approved for human consumption, medical, or veterinary use.